Show simple item record

dc.contributor.authorOffice of Marketing and Communications. Media Relations
dc.contributor.authorTorres, Luisa
dc.date.accessioned2017-07-11T18:03:38Z
dc.date.available2017-07-11T18:03:38Z
dc.date.issued2017-06-09
dc.identifier.urihttps://hdl.handle.net/1813/52042
dc.description.abstractThis blog post is about: Our brain is protected by a cellular barrier known as the blood-brain barrier. The difficulty in delivering therapeutic compounds to the brain lies partly in the existence of a blood-brain barrier protein known as P-glycoprotein, or P-gp. P-gp acts as a gatekeeper, allowing only essential nutrients to get into the brain while keeping toxic chemicals away. Although protective, P-gp is also a major obstacle to treating brain disorders such as glioblastoma, because it can block the entry of drugs that could otherwise be helpful to treat the disease. “P-gp is the bottleneck that blocks treatment of neurological conditions,” says Dr. Margaret Bynoe, professor of Immunology in the Department of Microbiology and Immunology. Bynoe and her colleagues target P-gp as a way to open the blood-brain barrier and get therapeutic compounds into the brain.
dc.language.isoen_US
dc.publisherCornell University, College of Veterinary Medicine
dc.subjectCornell University. College of Veterinary Medicine -- Periodicals.
dc.subjectBynoe, Margaret
dc.subjectTorres, Luisa
dc.title2017 Science@CornellVet: Overcoming the barrier to the brain: Repurposed drug gives hope to glioblastoma patient
dc.typearticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Statistics